October 5, 2020 09:41 AM EDTUpdated 02:38 PM

Harvard 'MacArthur genius’ Kevin Eggan steps in to run early-stage research at rare disease specialist BioMarin

John Carroll

Editor & Founder

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

Is there still hope for Summit's cancer drug buried in the data?

Updated: Omada Health rose 21% in its public market debut

EMA considers serious eye condition a ‘very rare’ side effect of semaglutide

At a crossroads, biotechs are passing on reverse mergers in 2025

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...